Beneficial role of crocin against doxorubicin-induced testicular damage in rats: insights into vimentin modulation
Öz
Purpose: Doxorubicin (DOX) is a wide-spectrum antibiotic used for chemotherapy. Its side effects limit treatment. Crocin is one of the carotenoids that has both anti-inflammatory and antioxidant activities. We aimed to evaluate the effects of crocin against doxorubicin-induced testicular damage in rats.
Materials and Methods: Forty Wistar rats were divided into four groups. Group 1: Control, Group 2: Crocin, Group 3: DOX, Group 4: DOX+Crocin (n=10, for all). Testis tissues were stained with Hematoxylin-Eosin. The diameters of seminiferous tubules were measured and the testicular mean histopathologic damage score (MHDS) was calculated. Vimentin expression in Sertoli cells was calculated as H-Score. Levels of Malondialdehyde (MDA), Glutathione (GSH), Catalase (CAT), and Superoxide dismutase (SOD) activities were determined in testis tissues. Total Antioxidant Status (TAS) and Total Oxidant Status (TOS) were also calculated.
Results: Atrophic seminiferous tubules were seen in the DOX group. Edema, vacuolization, and disorganization were present in the injured tubules. The MHDSs for the DOX group and control groups were 4.60±0.45 and 0.20±0.13, respectively. Both of these groups showed a significant difference. The histopathologic score was reduced after using crocin. Tubule damage considerably decreased while immunoexpression levels of vimentin and seminiferous tubule width significantly increased in the DOX+Crocin group compared to the DOX group. MDA and TOS levels were significantly increased after DOX treatment, and GSH, SOD, CAT, and TAS levels were significantly decreased. All biochemical indicators were greatly improved after receiving crocin.
Conclusion: Crocin supplementation exhibited adequate beneficial effects against the testicular damage of DOX-induced function by balancing the oxidant/antioxidant status.
Anahtar Kelimeler
Doxorubicin, crocin, testis, vimentin, oxidative stress.
Destekleyen Kurum
The research was supported by Karabuk University Scientifict Research Fund.
Proje Numarası
TYL-2020-2298
Etik Beyan
The Zonguldak Bulent Ecevit University Experimental Animals Ethics Committee approved the study (Protocol No. 2021-09-01/04).
Kaynakça
- Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C et al. Adriamycin, 14‐Hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng. 2000;67:704-13.
- Shinoda K, Mitsumori K, Yasuhara K, Uneyama C, Onodera H, Hirose M et al. Doxorubicin induces male germ cell apoptosis in rats. Arch Toxicol. 1999;73:274-81.
- Hou MI, Chrysis D, Nurmio M, Parvinen M, Eksborg S, Söder O et al. Doxorubicin induces apoptosis in germ line stem cells in the immature rat testis and amifostine cannot protect against this cytotoxicity. Cancer Res. 2005;65:9999-10005.
- Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 2014;10:853.
- Lalmuansangi C, Zosangzuali M, Lalremruati M, Tochhawng L, Siama Z. Evaluation of the protective effects of Ganoderma applanatum against doxorubicin-induced toxicity in Dalton's lymphoma ascites (DLA) bearing mice. Drug Chem Toxicol. 2022;45:1243-53.
- Yeh YC, Liu TJ, Wang LC, Lee HW, Ting CT, Lee WL et al. A standardized extract of Ginkgo biloba suppresses doxorubicin‐induced oxidative stress and p53‐mediated mitochondrial apoptosis in rat testes. Br J Pharmacol. 2009;156:48-61.
- Yang CC, Chen YT, Chen CH, Chiang JY, Zhen YY, Yip HK. Assessment of doxorubicin-induced mouse testicular damage by the novel second-harmonic generation microscopy. Am J Transl Res. 2017;9:5275-88.
- Rizk SM, Zaki HF, Mina MAM. Propolis attenuates doxorubicin-induced testicular toxicity in rats. Food Chem Toxicol. 2014;67:176-86.
- Mzabri I, Addi M, Berrichi A. Traditional and modern uses of saffron (Crocus sativus). Cosmetics. 2019;6:63.
- Lee IA, Lee JH, Baek NI, Kim DH. Antihyperlipidemic effect of crocin isolated from the fructus of Gardenia jasminoides and its metabolite crocetin. Biol Pharm Bull. 2005;28:2106-10.
